United Kingdom · Question · Written question
UIN 40092
Prostate Cancer: Hormone Treatments
Original
Introduced
20 March 2025
Last action
25 March 2025 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
25 March 2025
Summary
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential implications for his policies of the Institute of Cancer Research's report entitled Cost-utility analysis of adding abiraterone acetate plus prednisone/
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
20 March 2025
Written question
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential implications for his policies of the Institute of Cancer Research's report entitled Cost-utility analysis of adding abiraterone acetate plus prednisone/
Source: Commons
25 March 2025
Answer
Abiraterone has a United Kingdom marketing authorisation for the treatment of metastatic hormone-relapsed prostate cancer before chemotherapy is indicated, and for castration-resistant metastatic prostate cancer previously treated with a docetaxel-contain...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2025-03-20/40092
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1786973
- uk · wq-1786973 · source updated 25 March 2025